Physician profile
John G Schmidt
NPI 1295786507
$2,863.26
in general payments reported to CMS, 2019-2025
26 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $134 · 2021: $122 · 2022: $223 · 2023: $113 · 2024: $786 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,052.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.59 | 2021-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $432.85 | 2023-2025 | |
| Ucb, INC. | $354.03 | 2019-2025 | Rystiggo, Fintepla |
| Livanova USA, INC. | $223.22 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Sk Life Science, INC. | $175.11 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $146.09 | 2024-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $139.02 | 2019-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $132.43 | 2022-2025 | Rytary, Crexont |
| Mdd US Operations, LLC | $126.86 | 2022-2025 | Gocovri, Gocovri, Qelbree |
| Argenx US, INC. | $90.26 | 2024-2025 | Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $88.91 | 2023-2024 | Nuedexta |
| Lilly USA, LLC | $70.95 | 2019 | |
| Aucta Pharmaceuticals, INC. | $69.71 | 2024-2025 | Motpoly Xr |
| Janssen Biotech, INC. | $59.53 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $47.69 | 2025 | Wainua |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $42.00 | 2019 | |
| Amgen INC. | $26.57 | 2019 | |
| Kyowa Kirin, INC. | $22.95 | 2024 | Nourianz |
| Alnylam Pharmaceuticals INC. | $21.98 | 2025 | Amvuttra |
| Azurity Pharmaceuticals, INC. | $21.69 | 2024 | Horizant |
| Merz Pharmaceuticals, LLC | $21.46 | 2024 | Inbrija |
| Averitas Pharma INC. | $21.10 | 2024 | Qutenza |
| Eisai INC. | $19.86 | 2024 | |
| Supernus Pharmaceuticals, INC. | $16.71 | 2019 | |
| Adamas Pharmaceuticals, INC. | $15.07 | 2020 | |
| Emd Serono, INC. | $14.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.